Argent Trust Co Has $1.93 Million Holdings in Eli Lilly And Co (NYSE:LLY)

Share on StockTwits

Argent Trust Co raised its position in Eli Lilly And Co (NYSE:LLY) by 12.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,888 shares of the company’s stock after purchasing an additional 1,538 shares during the quarter. Argent Trust Co’s holdings in Eli Lilly And Co were worth $1,927,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. raised its stake in shares of Eli Lilly And Co by 5.6% in the 1st quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after purchasing an additional 3,420,265 shares during the period. Capital International Investors raised its stake in shares of Eli Lilly And Co by 3.6% in the 4th quarter. Capital International Investors now owns 26,055,933 shares of the company’s stock valued at $3,424,531,000 after purchasing an additional 910,672 shares during the period. FMR LLC raised its stake in shares of Eli Lilly And Co by 6.7% in the 4th quarter. FMR LLC now owns 14,235,227 shares of the company’s stock valued at $1,870,935,000 after purchasing an additional 888,413 shares during the period. Geode Capital Management LLC raised its stake in shares of Eli Lilly And Co by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 12,377,007 shares of the company’s stock valued at $1,623,438,000 after purchasing an additional 226,620 shares during the period. Finally, Jennison Associates LLC raised its stake in shares of Eli Lilly And Co by 125.9% in the 1st quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock valued at $1,413,841,000 after purchasing an additional 5,679,574 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP Stephen F. Fry sold 14,657 shares of the business’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $134.30, for a total transaction of $1,968,435.10. Following the completion of the sale, the senior vice president now owns 110,572 shares in the company, valued at $14,849,819.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Aarti S. Shah sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $150.00, for a total value of $300,000.00. Following the sale, the senior vice president now owns 19,087 shares of the company’s stock, valued at approximately $2,863,050. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 906,320 shares of company stock valued at $132,984,238. Corporate insiders own 0.09% of the company’s stock.

A number of research firms recently issued reports on LLY. Cfra lifted their target price on Eli Lilly And Co from $146.00 to $167.00 and gave the company a “hold” rating in a research report on Friday, April 24th. UBS Group downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and lifted their target price for the company from $157.00 to $158.00 in a research report on Monday, April 20th. Zacks Investment Research lowered their target price on Eli Lilly And Co to $156.00 in a research report on Wednesday, April 29th. Cowen lifted their target price on Eli Lilly And Co from $145.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Finally, Mizuho lifted their target price on Eli Lilly And Co from $148.00 to $155.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $158.64.

Eli Lilly And Co stock traded down $1.12 during midday trading on Friday, reaching $151.16. 2,322,495 shares of the company’s stock were exchanged, compared to its average volume of 2,875,585. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $164.90. The company has a debt-to-equity ratio of 4.37, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market cap of $145.65 billion, a price-to-earnings ratio of 24.99, a P/E/G ratio of 1.82 and a beta of 0.25. The stock’s 50-day simple moving average is $152.85 and its 200 day simple moving average is $136.00.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 23rd. The company reported $1.75 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.27. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. The business had revenue of $5.86 billion during the quarter, compared to analysts’ expectations of $5.48 billion. During the same quarter last year, the company posted $1.33 earnings per share. Eli Lilly And Co’s quarterly revenue was up 15.1% on a year-over-year basis. Research analysts forecast that Eli Lilly And Co will post 6.81 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.96%. The ex-dividend date of this dividend is Thursday, May 14th. Eli Lilly And Co’s dividend payout ratio is presently 49.01%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Why are analyst ratings important in trading stocks?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply